Phase III Study of Z-206

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222089

Enrollment

600

Registered

2013-05-24

Start date

2013-05-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

investigational material(s) Generic name etc : Z-206 INN of investigational material : Mesalazine Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Those who are with ulcerative colitis in remission state etc.

Exclusion criteria

Exclusion criteria: -Those who have a history of drug hypersensitivity to mesalazine or salicylic acid series etc.

Design outcomes

Primary

Measure	Time frame
The proportion of patients without relapse	—

Secondary

Measure	Time frame
The time to relapse	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026